(-0.46%) 5 048.42 points
(-0.98%) 38 086 points
(-0.64%) 15 612 points
(0.32%) $83.84
(-3.30%) $1.584
(0.12%) $2 345.40
(0.32%) $27.44
(1.06%) $930.30
(0.08%) $0.932
(0.13%) $10.97
(0.06%) $0.800
(0.02%) $92.18
Live Chart Being Loaded With Signals
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments...
Stats | |
---|---|
Today's Volume | 3.53M |
Average Volume | 4.79M |
Market Cap | 26.42B |
EPS | €0 ( 2024-03-04 ) |
Next earnings date | ( €2.32 ) 2024-05-14 |
Last Dividend | €2.40 ( 2023-05-02 ) |
Next Dividend | €0 ( N/A ) |
P/E | -8.99 |
ATR14 | €0.0180 (0.07%) |
Volume Correlation
Bayer AG Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Bayer AG Correlation - Currency/Commodity
Bayer AG Financials
Annual | 2023 |
Revenue: | €47.64B |
Gross Profit: | €27.89B (58.54 %) |
EPS: | €-2.99 |
Q4 | 2023 |
Revenue: | €11.86B |
Gross Profit: | €7.38B (62.18 %) |
EPS: | €1.360 |
Q3 | 2023 |
Revenue: | €10.34B |
Gross Profit: | €5.53B (53.47 %) |
EPS: | €-4.65 |
Q2 | 2023 |
Revenue: | €11.04B |
Gross Profit: | €6.33B (57.28 %) |
EPS: | €-1.920 |
Financial Reports:
No articles found.
Bayer AG Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€2.40 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €1.279 | 2000-05-02 |
Last Dividend | €2.40 | 2023-05-02 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 25 | -- |
Total Paid Out | €43.29 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.56 | -- |
Div. Sustainability Score | 3.24 | |
Div.Growth Potential Score | 2.19 | |
Div. Directional Score | 2.71 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
DYH.DE | Ex Dividend Knight | 2023-11-14 | Quarterly | 0 | 0.00% | |
MUB.DE | Ex Dividend Junior | 2023-08-11 | Annually | 0 | 0.00% | |
ADN1.DE | Ex Dividend Junior | 2023-06-02 | Annually | 0 | 0.00% | |
WCH.DE | Ex Dividend Junior | 2023-05-18 | Annually | 0 | 0.00% | |
FTE.DE | Ex Dividend Knight | 2023-12-04 | Semi-Annually | 0 | 0.00% | |
PBB.DE | Ex Dividend Junior | 2023-05-26 | Annually | 0 | 0.00% | |
BC8.DE | Ex Dividend Knight | 2023-05-26 | Annually | 0 | 0.00% | |
HNR1.DE | Ex Dividend Junior | 2023-05-04 | Annually | 0 | 0.00% | |
SAP.DE | Ex Dividend Knight | 2023-05-12 | Annually | 0 | 0.00% | |
COK.DE | Ex Dividend Knight | 2023-06-15 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.0617 | 1.500 | -1.235 | -1.852 | [0 - 0.5] |
returnOnAssetsTTM | -0.0238 | 1.200 | -0.795 | -0.954 | [0 - 0.3] |
returnOnEquityTTM | -0.0816 | 1.500 | -2.02 | -3.03 | [0.1 - 1] |
payoutRatioTTM | -0.806 | -1.000 | -8.06 | 8.06 | [0 - 1] |
currentRatioTTM | 1.259 | 0.800 | 8.70 | 6.96 | [1 - 3] |
quickRatioTTM | 0.784 | 0.800 | -0.0946 | -0.0757 | [0.8 - 2.5] |
cashRatioTTM | 0.201 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.355 | -1.500 | 4.08 | -6.11 | [0 - 0.6] |
interestCoverageTTM | 0.595 | 1.000 | -0.891 | -0.891 | [3 - 30] |
operatingCashFlowPerShareTTM | 4.85 | 2.00 | 8.38 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 2.05 | 2.00 | 8.97 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 1.332 | -1.500 | 4.67 | -7.01 | [0 - 2.5] |
grossProfitMarginTTM | 0.585 | 1.000 | 3.58 | 3.58 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0333 | 1.000 | -1.333 | -1.333 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.109 | 1.000 | -0.507 | -0.507 | [0.2 - 2] |
assetTurnoverTTM | 0.386 | 0.800 | -0.759 | -0.607 | [0.5 - 2] |
Total Score | 3.24 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -9.01 | 1.000 | -1.011 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0816 | 2.50 | -1.297 | -3.03 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 2.05 | 2.00 | 9.32 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 8.90 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 4.85 | 2.00 | 8.38 | 10.00 | [0 - 30] |
payoutRatioTTM | -0.806 | 1.500 | -8.06 | 8.06 | [0 - 1] |
pegRatioTTM | 0.115 | 1.500 | -2.57 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.100 | 1.000 | 10.00 | 0 | [0.1 - 0.5] |
Total Score | 2.19 |
Bayer AG
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators